<DOC>
	<DOCNO>NCT01122784</DOCNO>
	<brief_summary>Multicenter , randomize , single-blinded comparison two formulation rF1V vaccine single dosage 80 µg two 3-dose schedule 400 healthy , adult volunteer four parallel cohort . Two rF1V vaccine cohort ( N=160 ) two rF1V antigen-only cohort ( N=40 ) vaccinate two different three-dose schedule ( Days 0 , 56 182 Days 0 , 56 121 ) .</brief_summary>
	<brief_title>Randomized Single-Blinded Study Evaluate Safety Immunogenicity Recombinant Plague Vaccine With Without Adjuvant</brief_title>
	<detailed_description>The objective trial : compare safety rF1V vaccine administer two different schedule 28 day vaccination cumulatively Day 210 ; compare immunogenicity rF1V vaccine administer two different schedule 28 day Vaccination 3 ; compare safety immunogenicity rF1V vaccine administer two different schedule 12 month Vaccination 3 ; assess contribution adjuvant immunogenicity rF1V antigen .</detailed_description>
	<mesh_term>Plague</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . The volunteer sign ICF HIPAA authorization successfully complete ( least 90 % correct ) Test Understanding . 2 . The volunteer male female 18 55 year age ( inclusive ) time screen visit . 3 . The volunteer good health determine screen physician base upon medical history physical examination , include vital sign within acceptable range . 4 . The volunteer acceptable range laboratory parameter . 5 . The volunteer clinically significant abnormality ECG . 6 . The volunteer agree donate blood , plasma blood component therapeutic research purpose , except meet requirement study , time course study . 7 . The volunteer willing blood sample store future plague research study . 8 . The volunteer willing comply requirement protocol end study . 9 . Female volunteer must nonchildbearing potential , childbearing potential , must pregnant lactating must use acceptable contraception . 1 . History plague exposure disease previous vaccination plague vaccine . 2 . History allergy kanamycin aminoglycosides ( e.g. , gentamicin , tobramycin , amikacin ) . 3 . History anaphylaxis serious adverse reaction vaccine aluminum . 4 . Active tuberculosis systemic infectious process review system PE . 5 . History chronic illness require continuous frequent medical intervention acute/chronic untreated condition , multiple sclerosis , immunodeficiency , autoimmune immunosuppressive disease use immunosuppressive medication . 6 . Diabetes mellitus type require treatment insulin oral hypoglycemic drug . 7 . History chronic , severe recurrent joint pain ( four clinically significant occurrence per year require treatment remission ) arthritis etiology osteoarthritis . 8 . Previous diagnosis serious psychiatric disorder . 9 . Acute illness , evidence significant active infection evidence systemic disease time enrollment . 10 . Oral temperature &gt; 99.5°F . 11 . Receipt chemotherapeutic immunosuppressive agent , include highdose systemic glucocorticoid ( i.e. , prednisoneequivalent dose &gt; 20 mg/day ) . 12 . Receipt blood , blood product immune globulin . 13 . Receipt investigational drug therapy investigational implantable device intent receive investigational drug therapy device throughout study participation . 14 . Receipt investigational vaccine . 15 . Receipt intent license nonliving vaccine . 16 . Receipt license live vaccine within 60 day Vaccination 1 17 . Donation 400 mL blood 8 week Vaccination 1 . 18 . Occupational responsibility would prevent completion participation study . 19 . Weight body mass index ( BMI ) outside acceptable range . 20 . Positive screen laboratory test HIV antibody , HCV antibody HBsAg . 21 . A positive result urine drug screen test common substance abuse . 22 . Female volunteer pregnant lactating . 23 . The volunteer currently active duty U.S. military , member relative clinical site study staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Plague</keyword>
	<keyword>Vaccine</keyword>
</DOC>